ELI LILLY & CO (LLY)
US5324571083 - Common Stock
2 Dividend-Growth Stocks That Billionaire Izzy Englander Loves
Is Now a Good Time to Buy the Dip in Eli Lilly Stock?
Since Eli Lilly reported third-quarter earnings on Oct. 30, its shares have had a prolonged sell-off.
Why Viking Therapeutics Tumbled by More Than 10% This Week
Novo Nordisk stock plunges 20% after a trial of its latest weight loss drug disappoints
The Ozempic maker's stock tanked after its highly anticipated CagriSema drug trial showed an average of 22.7% weight loss, below expectations for 25%.
Eli Lilly's Obesity Drug Wins Approval In Sleep Apnea; Will ResMed Dive?
Eli Lilly gained FDA approval late Friday for its weight-loss drug, Zepbound, as a treatment for obstructive sleep apnea.
The FDA just approved Eli Lilly's Zepbound for sleep apnea — and Medicare coverage could be next
Zepbound was found to be five times more effective than a placebo in reducing breathing disruptions for people with obstructive sleep apnea
Lilly’s Zepbound Grabs First Drug Approval for Sleep Apnea in US
Eli Lilly & Co.’s weight-loss shot Zepbound won approval in the US as the first drug to treat sleep apnea, opening the door for broader insurance coverage of the blockbuster medicine.
FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea, expanding use in U.S.
The agency's decision expands the use of Zepbound and could potentially pave the way for Eli Lilly to gain broader insurance coverage for the treatment.
FDA approves Zepbound® (tirzepatide) as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity
/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved Zepbound® (tirzepatide) as the first and...
Healthcare Equity Strategist on Novo Setback
As Novo Nordisk experimental drug falls short of target, Mizuho Securities Healthcare Equity Strategist Jared Holz says Eli Lilly will remain the market leader. Holz also speaks with Scarlet Fu about any possible changes to Eli Lilly pricing. (Source: Bloomberg)
S&P 500 Movers: TSCO, LLY
Novo’s Obesity Shot Shortfall Shows Danger of Promising Too Much
Novo Nordisk A/S’s failure to meet its own bar for success on a next-generation obesity shot shows the danger of promising too much in the cut-throat market for weight-loss drugs.
Why Novo Nordisk Stock Got Destroyed Today, but Eli Lilly and Viking Stocks Are Up
Today's sell-off in Novo Nordisk may be the buying opportunity you've been waiting for.
Stock Market Tumbles, Treasury Yields Soar On Fed Rate Outlook: Weekly Review
Micron, Vertex, Novo Nordisk and Nike were notable losers on news.
Novo Nordisk stock sees biggest loss in more than 20 years on CagriSema results
Novo Nordisk stock sinks on news of its newest GLP-1 candidate.
Novo Nordisk stock sees biggest loss in 20 years on CagriSema results
Novo Nordisk stock sinks on news of its newest GLP-1 candidate.
A next-gen Ozempic falls short in a drug trial — and Novo Nordisk stock plunges 20%
Novo Nordisk (NVO) released mixed clinical-trial results for its potential Ozempic successor on Friday, leaving Wall Street disappointed.
LLY Stock Up as FDA Removes Mounjaro, Zepbound From Shortage List
Eli Lilly stock gains as the FDA removes tirzepatide drugs from the drug shortage list following a thorough reevaluation.
Lilly Rises After Novo Trial Miss Boosts Its Weight Loss Edge
Eli Lilly & Co. shares gained as its main rival in weight-loss drugs posted disappointing results from a clinical trial.
5 Things to Know Before the Stock Market Opens
News of the day for Dec. 20, 2024
Novo Nordisk Dives On CagriSegma Obesity Drug Trial. Eli Lilly, Viking Jump.
Eli Lilly and Viking Therapeutics jumped on Novo's setback.
Novo Nordisk shares plunge after CagriSema obesity drug trial disappoints
Novo Nordisk said on Friday its experimental next-generation obesity drug CagriSema helped patients cut their weight by 22.7% in a late-stage trial, below the 25% it had expected, wiping as much as $125 billion off its market value. The lower-than-expected weight loss from the drug candidate deals a blow to the Danish company's ambitions for a successor to its popular Wegovy that is more powerful than Eli Lilly's rival Zepbound, also known as Mounjaro. Investors and analysts had eagerly awaited this data as a test of Novo's case that it has a strong pipeline of drugs to follow Wegovy in the fiercely competitive anti-obesity market.
In weight loss battle, Novo and Lilly face growing offensive from licenced copies
As Novo Nordisk and Eli Lilly expand sales of their popular diabetes and weight-loss drugs, cheaper copies of their patented remedies are winning approval from some regulators overseas, posing a threat to the pharma giants' prices and market share. Since Novo's blockbuster Ozempic diabetes treatment was approved in the United States in 2017, regulators have greenlighted 22 medicines containing its main ingredient in Bangladesh, Laos, Russia and Paraguay as well as seven copies of Lilly's rival drugs in Bangladesh, according to a Reuters review.
FDA finalizes decision to end Lilly's GLP-1 shortage, analysts predict Novo will be next
The FDA decided the shortage for Eli Lilly's GLP-1 tirzepatide has finally come to an end.
FDA says knockoff versions of Lilly obesity drug must come off the market
Specialty pharmacies and online companies that have been selling off-brand copies of two blockbuster drugs for obesity and diabetes will need to phase out their versions next year under a federal decision issued Thursday. The Food and Drug Administration said that a nationwide shortage of Eli Lilly’s Zepbound and Mounjaro has been resolved, eliminating the need for copycat versions of the drugs that have become wildly popular with Americans trying to lose weight. The decision is a win for Lilly — which had been pressing the FDA to take the step for months — and is expected to impact how patients access the drugs, including how much they pay.
Noteworthy Thursday Option Activity: C, FCX, LLY
IBD 50's Hims & Hers Tumbles After FDA Pulls Lilly's Weight-Loss Drug From Shortage List
Compounders now have until late March to wind down their operations, depending on their licensing.
FDA says Eli Lilly's weight loss drug Zepbound is no longer in shortage
The decision that will eventually bar compounding pharmacies from making unbranded versions of the injection.
Lilly Weight-Loss Drug Shortage in US Has Ended, FDA Says
Eli Lilly & Co.’s weight-loss and diabetes drugs Mounjaro and Zepbound are no longer in short supply in the US, which means compounding pharmacies must stop making copycats in the coming months.
